Compare Levi Strauss & Co. (LEVI) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Teladoc Health Inc — how do they compare? Levi Strauss & Co. trades at $22.8 (market cap $8.75B), while Teladoc Health Inc trades at $6.67 (market cap $1.24B). The key difference: Levi Strauss & Co. is far larger — about 7.1× Teladoc Health Inc's market cap, and Levi Strauss & Co. pays a 2.81% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| LEVI | TDOC | |
|---|---|---|
Market Cap | $8.75B | $1.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $9.72 |
52-Week Low | $17.92 | $4.47 |
Enterprise Value | $10.07B | $1.50B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $22.47, down 4.75% today, but maintains strong fundamentals with a P/E of 16.24 and robust profitability metrics including 61.72% gross margin and 29.31% ROE. The company has beaten earnings estimates for three consecutive quarters and recently raised its dividend. Technical indicators show mixed signals with bearish moving averages but oversold RSI conditions, while analyst consensus remains strongly bullish with a $27.88 price target.
LEVI presents a compelling value opportunity with consistent earnings outperformance and digital transformation progress, though recent cybersecurity concerns and tariff pressures create near-term headwinds. The stock's current valuation discount to analyst targets and strong DTC growth strategy support upside potential, but investors should monitor execution risks and market volatility.
Teladoc Health (TDOC) trades at $6.62, down 6.5% on the day, reflecting investor concern after a Q2 2026 revenue miss and lowered full-year guidance. The stock is technically bearish with key support at $6, while fundamentals show revenue of $2.53B in 2025 but persistent net losses, with a negative net income margin of -7.13%. Recent news highlights multiple law firm investigations into the company following its guidance cut.
The outlook remains challenging due to weak BetterHelp performance and ongoing losses, though valuation ratios like P/S of 0.49 and EV/EBITDA of 6.96 suggest potential undervaluation. Risks include competitive pressures and legal scrutiny, but analyst consensus price target of $8.88 implies upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
